{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:13:25Z","timestamp":1789787605931,"version":"4.0.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"1149","license":[{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objective:<\/jats:title>\n                  <jats:p>Lung cancer is the leading cause of cancer-associated mortality worldwide. Central nervous system (CNS) metastasis is a prevalent and serious complication. The most common treatment for brain metastasis (BM) is still radiation therapy (RT). An increasing number of drugs have been shown to have intracranial activity or to sensitize tumours to radiotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p>Consecutive advanced multiline therapy failure in patients with non-small-cell lung cancer (NSCLC) with BM at the authors\u2019 hospital were retrospectively reviewed. Eligible patients were divided into two groups: Apatinib+RT group and RT group. Intracranial progression-free survival (PFS) and overall survival (OS) were analysed using the Kaplan\u2013Meier method.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>The median intracranial PFS for the RT group and Apatinib+RT group was 5.83 months and 11.81 months (p = 0.034). The median OS for the RT group and Apatinib+RT group was 9.02 months and 13.62 months (p = 0.311). The Apatinib+RT group had a better intracranial PFS, but there were no significant differences between the two arms in OS. The Apatinib+RT group had significantly reduced symptoms caused by BM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion:<\/jats:title>\n                  <jats:p>RT combined with apatinib could help to control intracranial metastases. The Apatinib+RT group had significantly reduced symptoms caused by BM and improved quality of life for patients, the safety of the two treatments was similar.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Advances in knowledge:<\/jats:title>\n                  <jats:p>Here, we propose that RT combined with apatinib can significantly relieve brain symptoms and tolerate side-effects without affecting OS in patients with BM following failure of multiline therapy for NSCLC. Of course, this paper is a retrospective origin study, and more powerful evidence is needed to demonstrate.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1259\/bjr.20220550","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T12:21:17Z","timestamp":1683721277000},"source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of apatinib+radiotherapy <i>vs<\/i> radiotherapy alone in patients with advanced multiline therapy failure for non small cell lung cancer with brain metastasis"],"prefix":"10.1093","volume":"96","author":[{"given":"Huanle","family":"Pan","sequence":"first","affiliation":[{"name":"Department of Radiation and Medical Oncology, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Radiation and Medical Oncology, The Second Affiliated Hospital of Wenzhou Medical University , Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanxiao","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Radiation and Medical Oncology, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yida","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation and Medical Oncology, The Second Affiliated Hospital of Wenzhou Medical University , Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Radiation and Medical Oncology, The Second Affiliated Hospital of Wenzhou Medical University , Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saijun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation and Medical Oncology, The Second Affiliated Hospital of Wenzhou Medical University , Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation and Medical Oncology, The Second Affiliated Hospital of Wenzhou Medical University , Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenkai","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Radiation and Medical Oncology, The Second Affiliated Hospital of Wenzhou Medical University , Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congying","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Radiation and Medical Oncology, The Second Affiliated Hospital of Wenzhou Medical University , Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaona","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Ultrasonography, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"key":"2024050216074318600_b1","first-page":"488","article-title":"Estimation and projection of lung cancer incidence and mortality in China","volume":"13","author":"Chen","year":"2010","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"2024050216074318600_b2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mam.2015.05.004","article-title":"Targeting EGFR in lung cancer: lessons learned and future perspectives","volume":"45","author":"Steuer","year":"2015","journal-title":"Mol Aspects Med"},{"key":"2024050216074318600_b3","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2007.02.006","article-title":"The elderly with synchronous non-small cell lung cancer and solitary brain metastasis: does palliative thoracic radiotherapy have a useful role?","volume":"57","author":"Ampil","year":"2007","journal-title":"Lung Cancer"},{"key":"2024050216074318600_b4","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1200\/JCO.2005.03.145","article-title":"Current management of brain metastases, with a focus on systemic options","volume":"23","author":"Langer","year":"2005","journal-title":"J Clin Oncol"},{"key":"2024050216074318600_b5","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1634\/theoncologist.12-7-884","article-title":"Multidisciplinary management of brain metastases","volume":"12","author":"Eichler","year":"2007","journal-title":"Oncologist"},{"key":"2024050216074318600_b6","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.canep.2013.06.003","article-title":"Predictive biochemical-markers for the development of brain metastases from lung cancer: clinical evidence and future directions","volume":"37","author":"Huang","year":"2013","journal-title":"Cancer Epidemiol"},{"key":"2024050216074318600_b7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/jamaoncol.2015.1145","article-title":"Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: secondary analysis of the JROSG 99-1 randomized clinical trial","volume":"1","author":"Aoyama","year":"2015","journal-title":"JAMA Oncol"},{"key":"2024050216074318600_b8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.lungcan.2012.09.016","article-title":"Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer","volume":"79","author":"Yang","year":"2013","journal-title":"Lung Cancer"},{"key":"2024050216074318600_b9","doi-asserted-by":"crossref","first-page":"S247","DOI":"10.1016\/j.lungcan.2004.07.968","article-title":"Treatment of brain metastases from non-small-cell lung cancer (NSCLC): radiotherapy","volume":"45","author":"Zabel","year":"2004","journal-title":"Lung Cancer"},{"key":"2024050216074318600_b10","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1053\/j.seminoncol.2004.07.012","article-title":"Management of brain metastases","volume":"31","author":"Bradley","year":"2004","journal-title":"Semin Oncol"},{"key":"2024050216074318600_b11","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1023\/A:1008318515795","article-title":"Chemotherapy for brain metastases of lung cancer: a review","volume":"10","author":"Postmus","year":"1999","journal-title":"Ann Oncol"},{"key":"2024050216074318600_b12","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/380435a0","article-title":"Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele","volume":"380","author":"Carmeliet","year":"1996","journal-title":"Nature"},{"key":"2024050216074318600_b13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","article-title":"Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis","volume":"86","author":"Hanahan","year":"1996","journal-title":"Cell"},{"key":"2024050216074318600_b14","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.lungcan.2009.02.013","article-title":"Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis","volume":"66","author":"Bonnesen","year":"2009","journal-title":"Lung Cancer"},{"key":"2024050216074318600_b15","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3727\/096504018X15288447760357","article-title":"Apatinib plus chemotherapy shows clinical activity in advanced NSCLC: a retrospective study","volume":"27","author":"Tang","year":"2019","journal-title":"Oncol Res"},{"key":"2024050216074318600_b16","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.ejca.2008.03.012","article-title":"The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients","volume":"44","author":"Kadota","year":"2008","journal-title":"Eur J Cancer"},{"key":"2024050216074318600_b17","article-title":"Expert consensus on diagnosis and treatment of brain metastases in lung cancer in China","author":"Yuankai","year":"2017","journal-title":"Chin J Lung Cancer"},{"key":"2024050216074318600_b18","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1002\/1097-0142(19940815)74:4+<1445::AID-CNCR2820741608>3.0.CO;2-#","article-title":"Quality of life and the patient with cancer. individual and policy implications","volume":"74","author":"GANZ PA","year":"1994","journal-title":"Cancer"},{"key":"2024050216074318600_b19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/ccd.1810270203","article-title":"Improved quality of life after PTCA: Generalizability and concerns","volume":"27","author":"Wenger","year":"1992","journal-title":"Cathet Cardiovasc Diagn"},{"key":"2024050216074318600_b20","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1158\/1078-0432.CCR-10-1564","article-title":"Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer","volume":"16","author":"Lockman","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2024050216074318600_b21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5301\/tj.5000441","article-title":"Stereotactic body radiotherapy of bone metastases in oligometastatic disease: prognostic factors of oncologic outcomes","volume":"102","author":"Ursino","year":"2016","journal-title":"Tumori"},{"key":"2024050216074318600_b22","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.cllc.2014.04.003","article-title":"An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer","volume":"15","author":"Ashworth","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"2024050216074318600_b23","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1200\/JCO.2005.04.6185","article-title":"Whole-Brain radiotherapy in the management of brain metastasis","volume":"24","author":"Khuntia","year":"2006","journal-title":"J Clin Oncol"},{"key":"2024050216074318600_b24","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/ajco.12834","article-title":"Clinical response to apatinib monotherapy in advanced non-small cell lung cancer","volume":"14","author":"Xu","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"2024050216074318600_b25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00517","article-title":"Clinical response to apatinib combined with brain radiotherapy in EGFR wild-type and ALK-negative lung adenocarcinoma with multiple brain metastases","volume":"10","author":"Ying","year":"2020","journal-title":"Front Oncol"},{"key":"2024050216074318600_b26","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1349-7006.2011.01939.x","article-title":"YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo","volume":"102","author":"Tian","year":"2011","journal-title":"Cancer Sci"},{"key":"2024050216074318600_b27","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.bcp.2011.12.007","article-title":"Apatinib (yn968d1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and abcb1-overexpressing leukemia cells","volume":"83","author":"Tong","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"2024050216074318600_b28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1517\/14656566.2015.981526","article-title":"Apatinib for the treatment of gastric cancer","volume":"16","author":"Geng","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"2024050216074318600_b29","doi-asserted-by":"crossref","first-page":"7981","DOI":"10.1158\/0008-5472.CAN-10-0111","article-title":"Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters","volume":"70","author":"Mi","year":"2010","journal-title":"Cancer Res"},{"key":"2024050216074318600_b30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040186","article-title":"Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1\/FLT1","volume":"4","author":"Lee","year":"2007","journal-title":"PLoS Med"},{"key":"2024050216074318600_b31","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.ejca.2008.03.012","article-title":"The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients","volume":"44","author":"Kadota","year":"2008","journal-title":"Eur J Cancer"},{"key":"2024050216074318600_b32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00428-010-0933-5","article-title":"Stage I colorectal carcinoma: VEGF immunohistochemical expression, microvessel density, and their correlation with clinical outcome","volume":"457","author":"Barresi","year":"2010","journal-title":"Virchows Arch"},{"key":"2024050216074318600_b33","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1158\/0008-5472.CAN-04-0074","article-title":"Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors","volume":"64","author":"Tong","year":"2004","journal-title":"Cancer Res"},{"key":"2024050216074318600_b34","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"2024050216074318600_b35","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1126\/science.284.5422.1994","article-title":"Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF","volume":"284","author":"Holash","year":"1999","journal-title":"Science"},{"key":"2024050216074318600_b36","first-page":"7","article-title":"Antiangiogenic therapy for cancer: current and emerging concepts","volume":"19","author":"Jain","year":"2005","journal-title":"Oncology (Williston Park)"},{"key":"2024050216074318600_b37","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1158\/1078-0432.CCR-10-1564","article-title":"Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer","volume":"16","author":"Lockman","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2024050216074318600_b38","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1158\/0008-5472.CAN-04-0074","article-title":"Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors","volume":"64","author":"Tong","year":"2004","journal-title":"Cancer Res"}],"container-title":["The British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/96\/1149\/20220550\/57370573\/bjr.20220550.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/96\/1149\/20220550\/57370573\/bjr.20220550.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T18:30:17Z","timestamp":1714674617000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/doi\/10.1259\/bjr.20220550\/7469127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,16]]},"references-count":38,"journal-issue":{"issue":"1149","published-online":{"date-parts":[[2023,5,16]]},"published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1259\/bjr.20220550","relation":{},"ISSN":["0007-1285","1748-880X"],"issn-type":[{"value":"0007-1285","type":"print"},{"value":"1748-880X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,1]]},"published":{"date-parts":[[2023,5,16]]},"article-number":"20220550"}}